Share Twitter LinkedIn Facebook Email Frederick Locke, MD Program Co-Leader, Immunology Moffitt Cancer Center, discusses Management Of Toxicity With CAR-T Therapies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
Inotuzumab Ozogamicin and Gemtuzumab Ozogamicin: A 2024 Guide to Managing Liver Toxicity and Cancer Treatment for Oncologists [40 Slides] Hematologic Malignancies 5 Mins Read
Non-Malignant Hematology Clinics: Essential Pioneers in the Evolving Hematologic Care Hematologic Malignancies 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read